Intact Vascular Announces Positive 1-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

June 26, 2020

Intact Vascular, Inc., announced the positive one-year results from its Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trial live stream.

Intact Vascular notes Co-Principal Investigator, Patrick Geraghty, M.D., Professor of Surgery and Radiology at the Washington University School of Medicine in St. Louis, Missouri, presented the one-year results, which successfully demonstrated sustained improvement in Rutherford category, toe-brachial index (TBI) and quality-of-life metrics following management of patients with post-PTA dissection with the Tack Endovascular System® (4F), in conjunction with excellent limb salvage and amputation free survival rates.

“Effective treatment of below-the-knee arterial disease is a critical component of amputation prevention. Now, with Tack implants, we have an on-label treatment for post-angioplasty dissection that provides excellent outcomes through the first year of follow-up,” commented Dr. Geraghty. “The Tack device is a valuable treatment option that augments an aggressive approach to endovascular limb salvage.”

Notably, the first vascular implant to receive U.S. Food and Drug (FDA) pre-market approval for below-the-knee (BTK) interventions, Tack® implants impressively demonstrated an 81.3% K-M Tacked Segment Patency and a 78.6% K-M Target Lesion Patency, with an 83.1% K-M Freedom from Clinically-Driven Reintervention at one-year. No fractures, embolization or migration of the Tack device were observed, confirming the durability of the minimal metal implants.

Additionally, in the critical limb ischemia (CLI) cohort, a population associated with high rates of amputation and mortality, Tack implants demonstrated remarkable 96.1% K-M Target Limb Salvage and 89.0% Amputation-Free Survival.

“This unprecedented trial is the first to investigate the safety and efficacy of a permanent vascular implant for repairing dissections in arteries below-the-knee. It enrolled a complex, predominantly CLI patient population that included 100% dissected vessels,” commented Peter Schneider, M.D., Co-Founder and Chief Medical Officer of Intact Vascular. “These excellent one-year data highlight the clinical importance of below-the-knee dissection repair and validate the sustained durability of Tack implants.”

Additional Co-Principal Investigators for the trial included George Adams, M.D., M.H.S., Director of Cardiovascular and Peripheral Vascular Research, UNC Rex Hospital, in Raleigh, North Carolina, and Andrej Schmidt, M.D., Division of Interventional Angiology, University Hospital Leipzig, Germany.

“We are extremely pleased with the results from TOBA II BTK,” commented Bruce Shook, President and CEO of Intact Vascular. “The data from this clinical study add to the expanding evidence that repairing dissections following angioplasty improves long term outcomes for patients suffering from peripheral arterial disease (PAD). With FDA approval in hand, we are moving forward to address the large unmet need that exists among patients suffering from the most serious form of this disease, critical limb ischemia. We are confident that the long-term data presented today will further accelerate adoption of this unique device, and we look forward to the continued commercial expansion of this first-of-its-kind technology.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.